Papers/PMID:29376219
Selenium for preventing cancer.
The Cochrane database of systematic reviews2018The record
5 findings · 1 compound · 5 endpoints · 5 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
5 findings
selenium atom — no detected effect on prostate cancer incidence
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“Two RCTs with 19,009 participants indicated that colorectal cancer was unaffected by selenium administration (RR 0.99, 95% CI 0.69 to 1.43), as were non-melanoma skin cancer (RR 1.16, 95% CI 0.30 to 4.42; 2 studies, 2027 participants), lung cancer (RR 1.16, 95% CI 0.89 to 1.50; 2 studies, 19,009 participants), breast cancer (RR 2.04, 95% CI 0.44 to 9.55; 1 study, 802 participants), bladder cancer (RR 1.07, 95% CI 0.76 to 1.52; 2 studies, 19,009 participants), and prostate cancer (RR 1.01, 95% CI 0.90 to 1.14; 4 studies, 18,942 participants).”
Quoted verbatim from Selenium for preventing cancer.. - Study
- meta-analysis
- Population
- Adults in randomised trials of selenium supplements versus placebo; analysis of trials with low risk of bias
Effect 1.01 risk ratio, 95% CI 0.9 to 1.14
Selenium for preventing cancer.2018PMID:29376219Permalink
selenium atom — no detected effect on lung cancer incidence
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“Two RCTs with 19,009 participants indicated that colorectal cancer was unaffected by selenium administration (RR 0.99, 95% CI 0.69 to 1.43), as were non-melanoma skin cancer (RR 1.16, 95% CI 0.30 to 4.42; 2 studies, 2027 participants), lung cancer (RR 1.16, 95% CI 0.89 to 1.50; 2 studies, 19,009 participants), breast cancer (RR 2.04, 95% CI 0.44 to 9.55; 1 study, 802 participants), bladder cancer (RR 1.07, 95% CI 0.76 to 1.52; 2 studies, 19,009 participants), and prostate cancer (RR 1.01, 95% CI 0.90 to 1.14; 4 studies, 18,942 participants).”
Quoted verbatim from Selenium for preventing cancer.. - Study
- meta-analysis
- Population
- Adults in randomised trials of selenium supplements versus placebo; analysis of trials with low risk of bias
Effect 1.16 risk ratio, 95% CI 0.89 to 1.5
Selenium for preventing cancer.2018PMID:29376219Permalink
selenium atom — no detected effect on colorectal cancer incidence
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×1“Two RCTs with 19,009 participants indicated that colorectal cancer was unaffected by selenium administration (RR 0.99, 95% CI 0.69 to 1.43), as were non-melanoma skin cancer (RR 1.16, 95% CI 0.30 to 4.42; 2 studies, 2027 participants), lung cancer (RR 1.16, 95% CI 0.89 to 1.50; 2 studies, 19,009 participants), breast cancer (RR 2.04, 95% CI 0.44 to 9.55; 1 study, 802 participants), bladder cancer (RR 1.07, 95% CI 0.76 to 1.52; 2 studies, 19,009 participants), and prostate cancer (RR 1.01, 95% CI 0.90 to 1.14; 4 studies, 18,942 participants).”
Quoted verbatim from Selenium for preventing cancer.. - Study
- meta-analysis
- Population
- Adults in randomised trials of selenium supplements versus placebo; analysis of trials with low risk of bias
Effect 0.99 risk ratio, 95% CI 0.69 to 1.43
Selenium for preventing cancer.2018PMID:29376219Permalink
selenium atom — no detected effect on urinary bladder cancer incidence
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×1“Two RCTs with 19,009 participants indicated that colorectal cancer was unaffected by selenium administration (RR 0.99, 95% CI 0.69 to 1.43), as were non-melanoma skin cancer (RR 1.16, 95% CI 0.30 to 4.42; 2 studies, 2027 participants), lung cancer (RR 1.16, 95% CI 0.89 to 1.50; 2 studies, 19,009 participants), breast cancer (RR 2.04, 95% CI 0.44 to 9.55; 1 study, 802 participants), bladder cancer (RR 1.07, 95% CI 0.76 to 1.52; 2 studies, 19,009 participants), and prostate cancer (RR 1.01, 95% CI 0.90 to 1.14; 4 studies, 18,942 participants).”
Quoted verbatim from Selenium for preventing cancer.. - Study
- meta-analysis
- Population
- Adults in randomised trials of selenium supplements versus placebo; analysis of trials with low risk of bias
Effect 1.07 risk ratio, 95% CI 0.76 to 1.52
Selenium for preventing cancer.2018PMID:29376219Permalink
selenium atom — no detected effect on breast cancer incidence
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×2“Two RCTs with 19,009 participants indicated that colorectal cancer was unaffected by selenium administration (RR 0.99, 95% CI 0.69 to 1.43), as were non-melanoma skin cancer (RR 1.16, 95% CI 0.30 to 4.42; 2 studies, 2027 participants), lung cancer (RR 1.16, 95% CI 0.89 to 1.50; 2 studies, 19,009 participants), breast cancer (RR 2.04, 95% CI 0.44 to 9.55; 1 study, 802 participants), bladder cancer (RR 1.07, 95% CI 0.76 to 1.52; 2 studies, 19,009 participants), and prostate cancer (RR 1.01, 95% CI 0.90 to 1.14; 4 studies, 18,942 participants).”
Quoted verbatim from Selenium for preventing cancer.. - Study
- meta-analysis
- Population
- Adults in randomised trials of selenium supplements versus placebo; analysis of trials with low risk of bias; one study only
Effect 2.04 risk ratio, 95% CI 0.44 to 9.55
Selenium for preventing cancer.2018PMID:29376219Permalink